Table 4 Characteristics of outcome measures in included trials by uveitis type

Uveitis related primary outcome

18

4

3

17

42

 Safety only

0

0

0

0

0

 Single efficacy

9

2

1

4

16

 Multiple separate efficacy

7

2

2

11

22

 Composite efficacy

2

0

0

2

4

Time to outcome measure in years (IQR)

0.04–0.5

0.4–3

1–2.5

0.5–2

0.2–2

 Activity

20

8

5

18

47

  ACC inactive SUN grade

7

3

–

4

–

  ACC 2 step change SUN grade

1

0

–

3

–

  Objective assessment AC Flare

1

1

0

0

–

  Other AC assessment

11

4

2

1

–

  Vitreous CC zero

–

3

0

1

–

  Vitreous 2 step change SUN grade

–

0

0

2

–

  Vitreous CC reduction

–

0

2

3

–

  Objective assessment vitreous

–

0

0

0

–

  Other vitreous assessment

–

5

1

1

–

  Macular oedema (MO)

3

2

3

13

21

  Objective assessment MO

2

2

3

12

19

  Use of topical steroids

1

1

1

4

7

  Use of systemic steroids

0

2

1

4

7

 Visual acuity

4

1

3

14

21

  Age appropriate measure

0

1

1

6

8

Reproducible assessment of cataract

0

0

0

0

0

Reproducible assessment of glaucoma

0

0

0

0

0

Reproducible assessment of band keratopathy

0

0

0

0

0

Vision related function

1

0

0

2

3

Vision related quality of life

1

0

2

0

3

Non-specific quality of life measure

1

0

1

1

3

 Validated for use in children

0

0

0

0

0